S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:CALA

Calithera Biosciences (CALA) Stock Forecast, Price & News

$0.23
+0.02 (+9.43%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.21
$0.24
50-Day Range
$0.16
$0.63
52-Week Range
$0.15
$2.59
Volume
2.12 million shs
Average Volume
4.06 million shs
Market Capitalization
$18.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.64
30 days | 90 days | 365 days | Advanced Chart
Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Calithera Biosciences logo

About Calithera Biosciences

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CALA
Fax
N/A
Employees
92
Year Founded
N/A

Sales & Book Value

Annual Sales
$9.75 million
Book Value
($0.04) per share

Profitability

Net Income
$-115.09 million
Pretax Margin
-1,113.11%

Debt

Price-To-Earnings

Miscellaneous

Free Float
69,351,000
Market Cap
$18.26 million
Optionable
Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/21/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.01 out of 5 stars

Medical Sector

568th out of 1,420 stocks

Pharmaceutical Preparations Industry

258th out of 679 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

Is Calithera Biosciences a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Calithera Biosciences stock.
View analyst ratings for Calithera Biosciences
or view top-rated stocks.

Are investors shorting Calithera Biosciences?

Calithera Biosciences saw a decrease in short interest in April. As of April 30th, there was short interest totaling 1,600,000 shares, a decrease of 37.0% from the April 15th total of 2,540,000 shares. Based on an average daily trading volume, of 2,290,000 shares, the short-interest ratio is currently 0.7 days.
View Calithera Biosciences' Short Interest
.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Calithera Biosciences
.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) released its quarterly earnings results on Tuesday, May, 10th. The biotechnology company reported ($0.18) EPS for the quarter, hitting the consensus estimate of ($0.18). During the same quarter last year, the business posted ($0.28) earnings per share.
View Calithera Biosciences' earnings history
.

What price target have analysts set for CALA?

4 brokerages have issued twelve-month price targets for Calithera Biosciences' stock. Their forecasts range from $1.50 to $4.00. On average, they expect Calithera Biosciences' stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 977.6% from the stock's current price.
View analysts' price targets for Calithera Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Calithera Biosciences' key executives?
Calithera Biosciences' management team includes the following people:
  • Dr. Susan M. Molineaux Ph.D., Founder, CEO, Pres & Director (Age 68, Pay $806.95k)
  • Ms. Stephanie Wong, CFO & Sec. (Age 48)
  • Ms. Sumita Ray J.D., Chief Legal & Admin. Officer (Age 47)
  • Dr. Eric B. Sjogren, Sr. VP of Drug Discovery (Age 65)
  • Dr. Christopher J. Molineaux Ph.D., Sr. VP of Devel. (Age 69)
  • Mr. Frank Parlati, Sr. VP of Research (Age 53)
  • Dr. Emil T. Kuriakose M.D., Chief Medical Officer
  • Dr. Susan B. Demo Ph.D., Sr. VP of R&D Operations
  • Dr. Allison Dillon Ph.D., Sr. VP of Commercial & Portfolio Strategy
What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.71%), Acadian Asset Management LLC (2.51%), Renaissance Technologies LLC (2.35%), Affinity Asset Advisors LLC (1.27%), Alyeska Investment Group L.P. (1.27%) and Empery Asset Management LP (0.99%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford and Susan Molineaux.
View institutional ownership trends for Calithera Biosciences
.

Which institutional investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., GSA Capital Partners LLP, Virtu Financial LLC, and HAP Trading LLC.
View insider buying and selling activity for Calithera Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Calithera Biosciences stock?

CALA stock was acquired by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Affinity Asset Advisors LLC, Empery Asset Management LP, Renaissance Technologies LLC, Truist Financial Corp, Bailard Inc., Acadian Asset Management LLC, and TSP Capital Management Group LLC.
View insider buying and selling activity for Calithera Biosciences
or or view top insider-buying stocks.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $0.23.

How much money does Calithera Biosciences make?

Calithera Biosciences has a market capitalization of $18.26 million and generates $9.75 million in revenue each year. The biotechnology company earns $-115.09 million in net income (profit) each year or ($1.440010) on an earnings per share basis.

How many employees does Calithera Biosciences have?

Calithera Biosciences employs 92 workers across the globe.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is www.calithera.com.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 870-1000 or via email at [email protected].

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.